Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

August 31, 1995

Primary Completion Date

August 7, 2002

Study Completion Date

May 18, 2017

Conditions
Mycobacterium Avium Complex Lung Disease
Interventions
DRUG

clarithromycin, rifabutin

Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.

Trial Locations (1)

75708

The University of Texas Health Science Center at Tyler, Tyler

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

The University of Texas Health Science Center at Tyler

OTHER

NCT00598897 - Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease | Biotech Hunter | Biotech Hunter